Medicsight’s ColonCAD computer-aided detection technology aims to assist radiologists in the detection of colorectal neoplasia by automatically highlighting suspicious areas on computed tomography colonography scan images.
The software may also help radiologists detect potentially malignant tumors at an early stage when treatment is most likely to be successful.
David Sumner, CEO of Medicsight, said: “This is another important milestone for Medicsight and our partners as we commercialize our technology globally.
“This regulatory approval in the Latin American market is another approval in a high growth Brazil, Russia, India and China market, following on from the Chinese State Food and Drug Administration approval announced in April 2008.”